Biogen
BIIB
1,046 hedge funds and large institutions have $30.7B invested in Biogen in 2026 Q2 according to their latest regulatory filings, with 127 funds opening new positions, 426 increasing their positions, 296 reducing their positions, and 83 closing their positions.
53% more first-time investments, than exits
New positions opened: 127 | Existing positions closed: 83
44% more repeat investments, than reductions
Existing positions increased: 426 | Existing positions reduced: 296
43% more call options, than puts
Call options by funds: $676M | Put options by funds: $473M
24% more capital invested
Capital invested by funds: $24.7B → $30.7B (+$5.98B)
14% more funds holding in top 10
Funds holding in top 10: 7 → 8 (+1)
4.42% more ownership
Funds ownership: 91.95% → 96.37% (+4.4%)
3% more funds holding
Funds holding: 1,012 → 1,046 (+34)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.03B |
| 2 |
Amundi
Paris,
France
|
+$139M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$96.9M |
| 4 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$88.5M |
| 5 |
Primecap Management
Pasadena,
California
|
+$75.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$200M |
| 2 |
VanEck Associates
New York
|
-$188M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$138M |
| 4 |
Boston Partners
Boston,
Massachusetts
|
-$83.5M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$73.6M |
BIIB Hedge Fund Activity: Q2 2026 in Review
1,046 of the 8,345 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q2 2026, worth a combined $30.7B — up 24% from $24.7B a quarter earlier.
Buyers outnumbered sellers: 127 funds opened new BIIB positions and 83 closed out — a net gain of 44 holders — while 426 added to existing stakes and 296 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $1.03B. The largest seller was T. Rowe Price Investment Management, cutting an estimated $200M.
- 1,046 institutional investors held Biogen (BIIB) as of Q2 2026, up from 1,012 in Q1 2026.
- Funds reported $30.7B of Biogen stock for Q2 2026, up 24% quarter-over-quarter.
- 127 funds opened new Biogen positions in Q2 2026 and 83 closed out, a net change of +44 holders.
- The largest Biogen buyer in Q2 2026 was Fidelity Investments, an estimated $1.03B added.
- The largest Biogen seller in Q2 2026 was T. Rowe Price Investment Management, an estimated $200M sold.
Based on aggregated 13F filings for Q2 2026.